RxC ProLOGS Tools and Frameworks

RxC ProLOGS Frameworks

Throughout the life cycle management process, we use RxC’s proprietary frameworks and tools in conjunction with client-provided input, resulting in a comprehensive and efficient engagement.  The tools and frameworks include:

Idea Generation Process

  • Leverages a cross-functional team to generate the initial list of life cycle management opportunities based on where the product is currently in its life cycle
  • Uses key market insights and competitive intelligence to understand unmet needs, trends, emerging science, and technological innovations
  • Collects input from across organization to be used in identifying and evaluating life cycle management opportunities

Comprehensive Market Assessment

  • Assesses life cycle opportunities from a scientific, clinical, regulatory, tech-ops, and commercial standpoint
  • Fosters acceptance and consensus across all areas of the organization

Key Criteria and Scoring Tool for Prioritizing Life Cycle Management Concepts

  • We work with the client to identify the key criteria important to the organization and often group them into categories such as: Scientific, Commercial, Operational, and Strategic
  • We provide weighting capabilities to help assign weightings to criteria to ensure alignment with the company’s goals and priorities
  • Enables scenario analysis for potential life cycle management opportunities

Life Cycle Concept Prioritization Framework

  • Overall framework that integrates results from the Comprehensive Market Assessment and the Key Criteria and Scoring Tool for Prioritizing Life Cycle Management Concepts to score and prioritize high potential opportunities

Business Case Development Framework

  • Facilitates the development of business cases for top life cycle opportunities identified using the Life Cycle Concept Prioritization Framework

Life Cycle Opportunity Valuation Tool

  • Provides measures for developing business cases for high-priority concepts including both strategic evaluations (potential value to patients, payers, and providers as well as value to the company) and financial evaluations (projected revenue, costs, profitability and financial impact)